Cargando…
Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen
Acquired hemophilia A (AHA) is a rare severe autoimmune bleeding disorder with significant morbidity and mortality. Although critical for disease control, there is no consensus for the best immunosuppressive regimen. Most authors use steroids first line, followed by other agents for steroid failures...
Autores principales: | Simon, Barbara, Ceglédi, Andrea, Dolgos, János, Farkas, Péter, Gaddh, Manila, Hankó, László, Horváth, Robert, Kaposi, Ambrus, Magyar, Lászlóné, Masszi, Tamás, Szederjesi, Attila, Wohner, Nikolett, Bodó, Imre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653022/ https://www.ncbi.nlm.nih.gov/pubmed/35930747 http://dx.doi.org/10.1182/blood.2022016873 |
Ejemplares similares
-
The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022) -
Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
por: Carney, Brian J., et al.
Publicado: (2021) -
Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022) -
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022) -
Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C
por: Jiang, Miao, et al.
Publicado: (2022)